Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Claris Lifesciences is currently trading at Rs. 178.10, up by 6.60 points or 3.85% from its previous closing of Rs. 171.50 on the BSE.
The scrip opened at Rs. 178.00 and has touched a high and low of Rs. 179.50 and Rs. 175.50 respectively. So far 4,840 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 292.20 on 05-Dec-2012 and a 52 week low of Rs. 142.05 on 18-Jun-2013.
The current market cap of the company is Rs. 1,136.00 crore.
The promoters holding in the company stood at 60.21% while Institutions and Non-Institutions held 24.15% and 13.79% respectively. Claris Lifesciences has completed the transfer of its Infusion business in India and Emerging Markets; to the joint venture (JV) ‘Claris-Otsuka’; with Otsuka Pharmaceutical Factory, Inc., Japan (OPF) and Mitsui & Company, Japan (Mitsui). The Infusion business includes Common Solutions, Anti-Infective, Plasma Volume Expanders and Parenteral Nutrition therapies for India and Emerging Markets.
The company has transferred two of its existing plants to the JV and will continue to hold 20% stake in the JV, while Otsuka and Mitsui will hold 60% and 20% respectively. The company has received a total cash consideration of Rs 1,050 crore as a part of the transaction from Claris-Otsuka. Claris-Otsuka is valued at Rs 1,313 crore.
Claris Lifesciences is one of the largest sterile injectables pharmaceutical companies in India. The company manufactures and markets products across various therapeutic segments including Anesthesia, Plasma Volume Expanders, Blood Products, Parenteral & Enteral Nutrition, Infusion therapy, Anti-infective and Renal Care.
| Company Name | CMP |
|---|---|
| Redington | 216.95 |
| Adani Enterprises | 3263.50 |
| Amrapali Industries | 15.35 |
| Rashi Peripheral | 341.75 |
| Compuage Infocom | 3.71 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
